Key result
Cardiomyocyte-specific overexpression of CYP2J2 completely prevented ventricular tachyarrhythmia inducibility (0% vs 47%) and reduced mortality (6% vs 42%) in mice subjected to chronic pressure overload.
Why the study?
Does CYP2J2 overexpression reduce arrhythmia susceptibility in mouse models of cardiac hypertrophy?
Population
Male transgenic mice with cardiomyocyte-specific overexpression of the human epoxygenase CYP2J2 and wildtype…
Comparison
Cardiomyocyte-specific overexpression of the… vs Wildtype littermates (WT)
Design
Preclinical
Follow-up
Up to 8 weeks (TAC) or 14 days (ISO)
Authors
Loading...
Hypothesis-generating for CYP2J2 in hypertrophy-related arrhythmias; leaves open translation to human disease.
Does CYP2J2 overexpression reduce arrhythmia susceptibility in mouse models of cardiac hypertrophy?
Absolute Event Rate: 0% vs 47%
p-value: p=<0.05
Enhanced cardiac EET biosynthesis via CYP2J2 overexpression protects against electrical remodeling and arrhythmia susceptibility in mouse models of maladaptive cardiac hypertrophy.
Westphal et al. (2013) studied Cardiac hypertrophy. CYP2J2 overexpression vs. Wildtype (WT) littermates was evaluated on Ventricular tachyarrhythmia inducibility 4 weeks after transverse aortic constriction (TAC) (p=<0.05). Cardiomyocyte-specific overexpression of CYP2J2 completely prevented ventricular tachyarrhythmia inducibility (0% vs 47%) and reduced mortality (6% vs 42%) in mice subjected to chronic pressure overload.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: